Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 06, 2024 15:52 ET
|
Tevogen Bio Inc
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024 08:30 ET
|
Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
June 06, 2024 08:00 ET
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
June 03, 2024 07:00 ET
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Global Tetraspecific Antibodies Clinical Trials & Market Report 2024: Pioneering the Future of Cancer Treatment, Shift Towards Tetraspecific Antibodies Amidst Drug Resistance Challenges
May 31, 2024 04:48 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's...
Allergy Vaccine Market Trends, Forecast and Competitive Analysis: A $3.6 Billion Market by 2030 with a CAGR of 7.5% from 2024 to 2030
May 31, 2024 04:18 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024 08:00 ET
|
Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease
May 22, 2024 06:55 ET
|
ANTION BIOSCIENCES SA
Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...